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Checkpoint kinase 2 (CHEK2) is as an important signal
transducer of cellular responses to DNA damage and
acts as a tumour suppressor gene. Mutations in the
CHEK2 gene have been shown to be associated with
increased risks to several cancers. In Poland four muta-
tions in CHEK2 gene (1100delC, IVS2+1G>A, I157T,
del5395) have been identified. Studies on our population
provided evidence that CHEK2 truncating mutations are
associated with increased risk of cancer in the thyroid,
breast and prostate. The I157T has been found to be
associated with increased risk of breast, prostate, colon,
kidney and thyroid cancer. The variability in penetrance
and cancer expression in mutation carriers probably can
be explained by influence of other genetic or environ-
mental factors.
Our preliminary data indicate that serum selenium level
is associated with breast/ovarian cancer risk in Polish
BRCA1 carriers. Both genes, BRCA1 and CHEK2, belong
to the same pathway, however clinical presentation of can-
cer phenotype in carriers of mutation in particular gene is
different eg. in respect to cancer location or tumour
pathological features. It may suggest presence of distinct
genetic factors which modify cancer risk in BRCA1 and
CHEK2 carriers.
Aim of the study was to check if Se concentration as
well as alterations in genes coding selenoproteins can be
a risk factors for cancer development in CHEK2 muta-
tion carriers. In this study we will determine serum Se
concentration and analyze genes coding selenoproteins
in ~100 CHEK2 mutation carriers affected by different
cancers (eg. breast, prostate, colon, kidney, lung, larynx)
and ~100 unaffected CHEK2 carriers matched to the
cancer cases.
We analysed for Se concentration and alterations of
13 selenoproteins in 58 CHEK2 carriers constituting 29
pairs, each composed of cancer patient and unaffected
control matched by: CHEK2 mutation type (missense or
protein truncating), sex, year of birth, smoking status
(pack-years +/- 20%) and cancer family history among I°
relatives.
We observed lower Se concentration in cancer
patients than in controls (70.5µg/l vs. 76.8 µg/l), how-
ever due to low number of pairs this difference was not
statistically significant. W ef o u n ds o m ee v i d e n c et h a t
specific genotypes in tested selenoprotein genes may be
associated with different cancer risk depending on Se
concentration, however this observation has also to be
verified in larger number of pairs.
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